NICHD Contraceptive Clinical Trials Network

The National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) awarded this Master IDIQ on August 15, 2013, with a shared ceiling of $35 million, but ordering closed on August 31, 2020 and is no longer accepting new task orders.

The vehicle funded clinical research to develop and evaluate contraceptive methods and reproductive health interventions. Task orders concentrated on male contraceptive efficacy trials, including studies of Nestorone gel, testosterone gel, DMAU (dimethandrolone undecanoate), and new chemical entities. All work was cost-reimbursable or firm fixed price, with no fee structures across the portfolio. Ultimate completion dates on recent awards extended through 2026, though the vehicle itself stopped accepting orders in 2020.

Ordering activity peaked in 2014 with eight awards, then slowed to three in 2013 and two in 2015. The portfolio comprises 13 total task orders issued between September 2013 and September 2015, with combined potential value of $33.7 million fully obligated. Two academic medical centers dominated the awards: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center received seven orders worth $19.9 million combined potential value, and University of Washington received six orders worth $13.8 million. All 13 orders funded NICHD programs exclusively, making customer concentration absolute.

Task-order values ranged from under $400,000 to approximately $11.8 million. The two largest awards, both issued to Lundquist Institute in September 2015, addressed male contraceptive efficacy clinical trials for Nestorone gel and testosterone gel, each exceeding $11.7 million. The vehicle carried no set-asides; all awards were unrestricted competitive.

Since ordering authority expired nearly six years ago and the vehicle is fully obligated, pursuit is not viable for new work.

The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded a Master IDIQ for the NICHD Contraceptive Clinical Trials Network (CCTN). The NIH, NICHD is the lead Federal agency for the conduct of basic, clinical and epidemiological research to develop new contraceptives and to evaluate existing methods of contraception and reproductive health.